NO20033398L - Tiazolyl-, oksazolyl-, pyrrolyl-, og imidazolyl- syreamidderivater nyttige som inhibitorer av PDE4 isozymer - Google Patents
Tiazolyl-, oksazolyl-, pyrrolyl-, og imidazolyl- syreamidderivater nyttige som inhibitorer av PDE4 isozymerInfo
- Publication number
- NO20033398L NO20033398L NO20033398A NO20033398A NO20033398L NO 20033398 L NO20033398 L NO 20033398L NO 20033398 A NO20033398 A NO 20033398A NO 20033398 A NO20033398 A NO 20033398A NO 20033398 L NO20033398 L NO 20033398L
- Authority
- NO
- Norway
- Prior art keywords
- oxazolyl
- pyrrolyl
- thiazolyl
- inhibitors
- acid amide
- Prior art date
Links
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- 108010044467 Isoenzymes Proteins 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- -1 imidazolyl acid amide Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002971 oxazolyl group Chemical class 0.000 title 1
- 125000000168 pyrrolyl group Chemical class 0.000 title 1
- 125000000335 thiazolyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26548601P | 2001-01-31 | 2001-01-31 | |
| PCT/IB2001/002728 WO2002060898A1 (en) | 2001-01-31 | 2001-12-24 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033398D0 NO20033398D0 (no) | 2003-07-30 |
| NO20033398L true NO20033398L (no) | 2003-09-29 |
Family
ID=23010641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033398A NO20033398L (no) | 2001-01-31 | 2003-07-30 | Tiazolyl-, oksazolyl-, pyrrolyl-, og imidazolyl- syreamidderivater nyttige som inhibitorer av PDE4 isozymer |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6559168B2 (no) |
| EP (1) | EP1355907A1 (no) |
| JP (1) | JP2004518691A (no) |
| KR (1) | KR20030072614A (no) |
| CN (1) | CN1489588A (no) |
| BG (1) | BG108039A (no) |
| BR (1) | BR0116850A (no) |
| CA (1) | CA2436551A1 (no) |
| CR (1) | CR7038A (no) |
| CZ (1) | CZ20031903A3 (no) |
| EA (1) | EA200300622A1 (no) |
| EC (1) | ECSP034683A (no) |
| EE (1) | EE200300362A (no) |
| HU (1) | HUP0401305A2 (no) |
| IL (1) | IL156412A0 (no) |
| IS (1) | IS6844A (no) |
| MA (1) | MA26985A1 (no) |
| MX (1) | MXPA03006886A (no) |
| NO (1) | NO20033398L (no) |
| OA (1) | OA12542A (no) |
| PL (1) | PL365443A1 (no) |
| TN (1) | TNSN03050A1 (no) |
| WO (1) | WO2002060898A1 (no) |
| ZA (1) | ZA200305769B (no) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1371650A4 (en) * | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| EP1389467B1 (en) * | 2001-05-23 | 2013-07-03 | Mitsubishi Tanabe Pharma Corporation | Therapeutic composition for the regenerative treatment of cartilage diseases |
| CA2447619A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for accelerating bone fracture healing |
| US20040235794A1 (en) * | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| CN100506807C (zh) * | 2001-12-21 | 2009-07-01 | 诺沃挪第克公司 | 作为gk活化剂的酰胺衍生物 |
| US6696473B2 (en) * | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| GB0201677D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US20040072726A1 (en) * | 2002-02-01 | 2004-04-15 | Ryuichi Morishita | Decoy-containing pharmaceutical compositions and method of using the same |
| US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| AU2003243921B2 (en) * | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| GB0217196D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
| FI114917B (fi) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
| JP2006508996A (ja) * | 2002-11-27 | 2006-03-16 | アルタナ ファルマ アクチエンゲゼルシャフト | 悪液質の治療における使用のための、ｐｄｅ４及びｐｄｅ３／４インヒビター |
| EP1424101A3 (en) * | 2002-11-29 | 2004-08-18 | NOZAKI, Masako | Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis |
| US7148248B2 (en) * | 2002-11-29 | 2006-12-12 | Masako Nozaki | Method of treating or inhibiting the development of brain inflammation and sepsis |
| CA2511521C (en) | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20050079548A1 (en) * | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| WO2005023253A1 (en) * | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP2444397A1 (en) * | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
| US20090042951A1 (en) * | 2004-02-20 | 2009-02-12 | Robert Danziger | Blood Pressure Reduction in Salt-Sensitive Hypertension |
| WO2005102388A1 (ja) | 2004-04-26 | 2005-11-03 | Ono Pharmaceutical Co., Ltd. | 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物 |
| EP1742627A4 (en) * | 2004-05-06 | 2009-08-26 | Plexxikon Inc | PDE4B HEMMER AND ITS USE |
| KR101242310B1 (ko) * | 2004-05-17 | 2013-03-12 | 오츠카 세이야쿠 가부시키가이샤 | 티아졸 화합물 및 그의 용도 |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| CN101048407A (zh) * | 2004-09-03 | 2007-10-03 | 普莱希科公司 | 双环杂芳基pde4b抑制剂 |
| US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
| WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| EA015382B1 (ru) | 2005-03-08 | 2011-08-30 | Никомед Гмбх | Применение рофлумиласта для лечения сахарного диабета типа 2 |
| PL2366393T3 (pl) * | 2005-04-19 | 2014-01-31 | Takeda Gmbh | Roflumilast do leczenia nadciśnienia płucnego |
| US7999114B2 (en) * | 2005-07-08 | 2011-08-16 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| CA2615938C (en) * | 2005-07-14 | 2014-04-29 | Novo-Nordisk A/S | Urea glucokinase activators |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CN1954882A (zh) * | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2008017164A1 (en) * | 2006-08-11 | 2008-02-14 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| CA2675111C (en) * | 2007-01-11 | 2016-04-05 | Novo Nordisk A\S | Urea glucokinase activators |
| WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| CA2722586A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| JP2011516426A (ja) * | 2008-03-28 | 2011-05-26 | コンサート ファーマシューティカルズ インコーポレイテッド | キナゾリン誘導体および治療方法 |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| AR074874A1 (es) | 2008-12-23 | 2011-02-16 | Biosource Pharm Inc | Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto. |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AU2010260249B2 (en) * | 2009-06-18 | 2013-09-05 | Concert Pharmaceuticals, Inc. | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| TR201807659T4 (tr) | 2013-06-12 | 2018-06-21 | Kaken Pharma Co Ltd | 4-alkinil imidazol türevi ve etken madde olarak bunu içeren ilaç. |
| AR101696A1 (es) * | 2014-09-12 | 2017-01-04 | Lilly Co Eli | Compuestos de azetidiniloxifenilpirrolidina |
| CN108794620A (zh) * | 2017-05-04 | 2018-11-13 | 南开大学 | 茶碱的偶联物及其制备方法与应用 |
| US11866482B2 (en) | 2018-02-07 | 2024-01-09 | Duke University | System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators |
| EP4487909A3 (en) | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| WO2025063819A1 (ko) * | 2023-09-21 | 2025-03-27 | 오토텔릭바이오 주식회사 | 티아졸 유도체 화합물을 포함하는 장섬유화증 치료용 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2140772A5 (en) | 1971-06-07 | 1973-01-19 | Aries Robert | Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics |
| US4270946A (en) * | 1979-10-01 | 1981-06-02 | Stauffer Chemical Company | N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof |
| US4692185A (en) * | 1986-01-13 | 1987-09-08 | Stauffer Chemical Company | N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides |
| US4861891A (en) | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
| DE69130605T2 (de) | 1991-02-27 | 1999-05-20 | Lacer, S.A., Barcelona | Antihypertensive N-(alpha-substituiertes Pyridyl)-carbonyldipeptide |
| DE4200323A1 (de) | 1992-01-09 | 1993-07-15 | Bayer Ag | Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten |
| EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| JPH08511805A (ja) | 1993-06-18 | 1996-12-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| JP3406689B2 (ja) | 1994-03-15 | 2003-05-12 | 株式会社大塚製薬工場 | ナフチリジン及びピリドピラジン誘導体 |
| US5618027A (en) * | 1994-07-20 | 1997-04-08 | Nevrekar; Venkatesh R. | Gate valve |
| JPH10511398A (ja) | 1994-12-23 | 1998-11-04 | スミスクライン・ビーチャム・コーポレイション | ４，４−（二置換）シクロヘキサン−１−カルボキシレート単量体および関連する化合物 |
| TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US5922557A (en) | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
| US6380218B1 (en) | 1997-04-04 | 2002-04-30 | Pfizer Inc | Nicotinamide derivatives |
| GB9715584D0 (en) * | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| UA67753C2 (uk) | 1997-10-10 | 2004-07-15 | Смітклайн Бічам Корпорейшн | Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| AR015190A1 (es) | 1997-10-23 | 2001-04-18 | Smithkline Beecham Corp | Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento |
| AU2700201A (en) * | 2000-01-31 | 2001-08-14 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| DZ3406A1 (no) * | 2000-01-31 | 2001-08-09 | Pfizer Prod Inc |
-
2001
- 2001-12-24 KR KR10-2003-7010071A patent/KR20030072614A/ko not_active Ceased
- 2001-12-24 OA OA1200300177A patent/OA12542A/en unknown
- 2001-12-24 EA EA200300622A patent/EA200300622A1/ru unknown
- 2001-12-24 EP EP01273600A patent/EP1355907A1/en not_active Withdrawn
- 2001-12-24 WO PCT/IB2001/002728 patent/WO2002060898A1/en not_active Ceased
- 2001-12-24 EE EEP200300362A patent/EE200300362A/xx unknown
- 2001-12-24 PL PL01365443A patent/PL365443A1/xx not_active Application Discontinuation
- 2001-12-24 IL IL15641201A patent/IL156412A0/xx unknown
- 2001-12-24 CA CA002436551A patent/CA2436551A1/en not_active Abandoned
- 2001-12-24 CZ CZ20031903A patent/CZ20031903A3/cs unknown
- 2001-12-24 BR BR0116850-9A patent/BR0116850A/pt not_active IP Right Cessation
- 2001-12-24 JP JP2002561466A patent/JP2004518691A/ja active Pending
- 2001-12-24 CN CNA018224431A patent/CN1489588A/zh active Pending
- 2001-12-24 MX MXPA03006886A patent/MXPA03006886A/es active IP Right Grant
- 2001-12-24 HU HU0401305A patent/HUP0401305A2/hu unknown
-
2002
- 2002-01-31 US US10/062,145 patent/US6559168B2/en not_active Expired - Fee Related
- 2002-11-20 US US10/300,959 patent/US6894041B2/en not_active Expired - Fee Related
- 2002-11-20 US US10/300,950 patent/US6869945B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 IS IS6844A patent/IS6844A/is unknown
- 2003-07-04 EC EC2003004683A patent/ECSP034683A/es unknown
- 2003-07-08 TN TNPCT/IB2001/002728A patent/TNSN03050A1/fr unknown
- 2003-07-21 MA MA27243A patent/MA26985A1/fr unknown
- 2003-07-25 ZA ZA200305769A patent/ZA200305769B/en unknown
- 2003-07-28 BG BG108039A patent/BG108039A/xx unknown
- 2003-07-29 CR CR7038A patent/CR7038A/es not_active Application Discontinuation
- 2003-07-30 NO NO20033398A patent/NO20033398L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030186974A1 (en) | 2003-10-02 |
| CR7038A (es) | 2004-04-22 |
| MA26985A1 (fr) | 2004-12-20 |
| PL365443A1 (en) | 2005-01-10 |
| OA12542A (en) | 2006-06-05 |
| JP2004518691A (ja) | 2004-06-24 |
| US6559168B2 (en) | 2003-05-06 |
| HUP0401305A2 (hu) | 2004-10-28 |
| US20030130254A1 (en) | 2003-07-10 |
| BG108039A (en) | 2004-07-30 |
| ZA200305769B (en) | 2004-10-25 |
| CZ20031903A3 (cs) | 2004-07-14 |
| NO20033398D0 (no) | 2003-07-30 |
| CA2436551A1 (en) | 2002-08-08 |
| BR0116850A (pt) | 2004-02-25 |
| US6869945B2 (en) | 2005-03-22 |
| EA200300622A1 (ru) | 2003-12-25 |
| AU2002222429A2 (no) | 2002-08-12 |
| ECSP034683A (es) | 2003-08-29 |
| US6894041B2 (en) | 2005-05-17 |
| MXPA03006886A (es) | 2003-11-13 |
| WO2002060898A1 (en) | 2002-08-08 |
| US20020123520A1 (en) | 2002-09-05 |
| IS6844A (is) | 2003-06-16 |
| KR20030072614A (ko) | 2003-09-15 |
| IL156412A0 (en) | 2004-01-04 |
| EE200300362A (et) | 2003-12-15 |
| EP1355907A1 (en) | 2003-10-29 |
| CN1489588A (zh) | 2004-04-14 |
| TNSN03050A1 (fr) | 2005-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033398L (no) | Tiazolyl-, oksazolyl-, pyrrolyl-, og imidazolyl- syreamidderivater nyttige som inhibitorer av PDE4 isozymer | |
| NO20033397D0 (no) | Nikotinamidbiarylderivater nyttige som inhibitorer av PDE4 isozymer | |
| HUP0401233A3 (en) | Aromatic hydroxamic acid derivatives useful as hdac inhibitors | |
| DK1318980T3 (da) | Hydroxamatderivater, der kan anvendes som deacetylaseinhibitorer | |
| NO20043793L (no) | Nikotinamidderivater anvendelige som PDE4 inhibitorer | |
| AU2003237121A1 (en) | Pyrrole derivatives as inhibitors of erk2 and uses thereof | |
| DE60319430D1 (de) | R- und fgfr-inhibitoren | |
| DK1751108T3 (da) | Adamantyl-acetamidderivater som inhibitorer for 11-beta-hydroxysteroid-dehydrogenase-type 1-enzymet | |
| IS7792A (is) | Hýdantóínafleiður og notkun þeirra sem TACE hemla | |
| NO20033399L (no) | Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer | |
| NO20033742D0 (no) | Omega-aminoalkylamider av R-2-arylpropionsyrer som inhibitorer av polymofonukle¶re og mononukle¶re cellers kjemotakse | |
| SI1492785T1 (sl) | 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3 | |
| NO20043004L (no) | 4-oksokinolin forbindelse og anvendelse derav som HIV-integraseinhibitor | |
| PL378181A1 (pl) | Pochodne kwasu hydroksamidowego jako inhibitory deacetylazy histonowej (HDAC) | |
| EP1496896A4 (en) | AKT INHIBITORS EFFECT | |
| EP1496906A4 (en) | HEMMER OF ACT ACTIVITY | |
| PL377696A1 (pl) | Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC | |
| NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
| NO20032441D0 (no) | Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer | |
| ATE384530T1 (de) | 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer | |
| PL371439A1 (en) | Phthalimido derivatives as inhibitors of monoamine oxidase b | |
| NO20023921D0 (no) | Derivater av thiazepinylhydroksamisk syre som inhibitorer av matriks metalloproteinase | |
| PL363771A1 (en) | Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors | |
| AU2003277878A1 (en) | Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors | |
| DE60335525D1 (de) | 2,3-Diaryl-Pyrazolidine Derivate als Neurotensin abbauende Enzyme-Inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |